LUMO
Lumos Pharma Inc

4,881
Loading...
Loading...
News
all
press releases
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LUMO, ALTR, STAF on Behalf of Shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LUMO, ALTR, STAF on Behalf of Shareholders SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LUMO, ALTR, STAF on Behalf of Shareholders...
PR Newswire·11mo ago
News Placeholder
More News
News Placeholder
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LUMO, BMTX, NXU on Behalf of Shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LUMO, BMTX, NXU on Behalf of Shareholders SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LUMO, BMTX, NXU on Behalf of Shareholders...
PR Newswire·11mo ago
News Placeholder
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Lumos Pharma, Inc.
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Lumos Pharma, Inc. ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Lumos Pharma, Inc. PR Newswire NEW YORK, Oct. 23...
PR Newswire·11mo ago
News Placeholder
LUMO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Lumos Pharma, Inc. Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Lumos Pharma, Inc. (NASDAQ: LUMO) to Double Point Ventures LLC for $4.25 per share in cash, plus one...
Business Wire·11mo ago
News Placeholder
Shareholder Alert: Ademi LLP Investigates Whether Lumos Pharma, Inc. Is Obtaining a Fair Price for Its Public Shareholders
Ademi LLP is investigating Lumos Pharma (NASDAQ: LUMO) for possible breaches of fiduciary duty and other violations of law in its transaction with Double Point Ventures. Click here to learn how to...
Business Wire·11mo ago
News Placeholder
Lumos Pharma (NASDAQ:LUMO) Earns Buy Rating from HC Wainwright
HC Wainwright reissued their buy rating on shares of Lumos Pharma (NASDAQ:LUMO Free Report) in a report published on Wednesday morning, Benzinga reports. They currently have a $28.00 target...
Ticker Report·2y ago
News Placeholder
Lumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042
AUSTIN, Texas, March 20, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency...
Globe Newswire·2y ago
News Placeholder
Analysts Are Bullish on Top Healthcare Stocks: Poseida Therapeutics (PSTX), Lumos Pharma (LUMO)
Theres a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Poseida Therapeutics (PSTX Research Report), Lumos Pharma...
TipRanks Financial Blog·2y ago
News Placeholder
Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update
End of Phase 2 Meeting to Occur in Q2 2024, Initiation of LUM-201 Phase 3 Trial Expected in Q4 2024 Previously Announced Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201...
Globe Newswire·2y ago
News Placeholder
Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024
AUSTIN, Texas, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD...
Globe Newswire·2y ago

Latest LUMO News

View

Advertisement|Remove ads.

Advertisement|Remove ads.